Showing results (231-240 of 439) with videos related to
Sort By:
Pageof 44
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.Annals of Hematology|January 8, 2021
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)Massimo Breccia, Simone Celant, Pier Paolo Olimpieri, et al.Journal of Clinical Medicine|August 26, 2023
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA SurveyMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.Leukemia Research|August 19, 2007
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rateGiuliana Alimena, Massimo Breccia, Luigia Luciano, et al.Mediterranean Journal of Hematology and Infectious Diseases|March 29, 2014
Early and late complications related to central venous catheters in hematological malignancies: a retrospective analysis of 1102 patientsSalvatore Giacomo Morano, Lorenzo Coppola, Roberto Latagliata, et al.Haematologica|May 14, 2026
Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in ItalyMassimo Breccia, Alessandra Iurlo, Fabrizio Pane, et al.International Journal of Hematology|August 25, 2009
Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term resultsRoberto Latagliata, Angela Rago, Antonio Spadea, et al.Haematologica|November 22, 2011
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experienceCorrado Girmenia, Anna Maria Frustaci, Giuseppe Gentile, et al.Acta Haematologica|December 5, 2012
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemiaRoberto Latagliata, Alessandro Isidori, Massimo Breccia, et al.Blood|November 4, 2011
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocolsMassimo Breccia, Luca Mazzarella, Vincenzo Bagnardi, et al.Pageof 44